Isabelle Mahé on Reduced Dose Apixaban for Cancer-Associated VTE: API-CAT Trial Results
Isabelle Mahé, Head of Internal Medicine, Louis Mourier Hospital, APHP, Paris Cité University, reposted from Syed Saad Mahmood on LinkedIn:
”Thank you very much for the opportunity to discuss the results of the API-CAT Study adressing the extended anticoagulant treatment in patients with cancer associated thrombosis!”
Syed Saad Mahmood, System Director, Cardio-Oncology at Catholic Health, shared on LinkedIn:
”*St Francis Heart Center, NY CardioOncology Journal Club*
Dr. Isabelle Mahe (Université Paris Cité, France) joined us to discuss *API-CAT trial* evaluating whether among active cancer patients with venous thromboembolism, tx with a reduced dose oral anticoagulant is effective in preventing recurrent thromboembolic events and reduced bleeding”
Find more from Cardio-Oncology Journal Club.
Watch the full episode here.
Stay updated on the latest advancements in hemostasis research with Hemostasis Today.
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda